MAY 2008 - PETERBOROUGH & TORONTO, CANADA MEETING - SIXTH INTERNATIONAL SYMPOSIUM

SPEAKERS

Michel Bazinet - Canada

Michel Bazinet, MD, is Chairman and CEO of REPLICor Inc. Previously, Dr. Bazinet was the founder and medical director of Mediconsult Inc. This company was created in April 1996, did an IPO ($65 Million USD) (NASDAQ: MCNS) in 1999 and was merged with Andrx Corporation in the year 2000. Prior to his involvement with Mediconsult, Dr. Bazinet worked as Assistant Professor in the departments of urology and oncology at McGill University in Montreal. He did his medical training at Sherbrooke University, his urology training at McGill University after which he did a 3-year fellowship in human tumor immunology and urologic oncology at the Memorial Sloan-Kettering Cancer Center in New York from 1984 to 1987. Dr. Bazinet serves as a member of the board of directors for Altair Nanotechnologies Inc. (Reno, Nevada, USA), (NASDAQ: ALTI) and for Bioniche Life Sciences Inc. (Belleville, Ontario, Canada) (TSX: BNC).

About REPLICor Inc.

REPLICor is developing a broad-spectrum antiviral drug called REP 9AC which has the broadest spectrum of antiviral activity ever described for a single chemical entity. It is active against 12 viral families out of 18 that can affect humans. REP 9AC is active against many important viruses including hepatitis C, hepatitis B and influenza (including avian H5N1), and is effective in treating several viral infections in animals. It has been shown to be well tolerated in multiple animal studies.

Bruno Canard – France

Dr. Canard is with the Architecture et Fonction des Macromolecules Biologiques in France. He is the Head of the Department of Structural Virology and Drug Design. His laboratory focuses on: Viral replicases: structure mechanism & drug design; structural disorder within viruses; and proteins from emergent viruses and parasitology.

Jeremy P. Carver - Canada

Jeremy P. Carver is the co-founder and CEO of ICAV. He is also Chair of the Advisory Committee of the NRC Institute for Biological Sciences and is a Director of Translational Medicines, a Boston biotechnology company. Dr. Carver is an Emeritus Professor of the University of Toronto and an Honorary Conjunct Professor at Trent University. Dr. Carver chaired the Board of the Protein Engineering Network of Centres of Excellence (PENCE) from 2002 until 2006. From 1994 to 2002 he was the Founding President, CEO and CSO of GlycoDesign Inc. He was a Professor and Associate Dean in the Faculty of Medicine at the University of Toronto (1968 – 1994), a Helen Hay Whitney Postdoctoral Fellow at Oxford University (1966-68) and a World Trade Visiting Scientist at IBM Watson Labs, New York (1977).

Michel Chrétien - Canada

Michel Chrétien is co-founder of ICAV and a Senior Scientist at the Ottawa Health Research Institute. Ten years ago, his group discovered proprotein convertases, enzymes that are involved in a number of debilitating conditions including: hypercholesterolemia, cancer, atherosclerosis, malaria and viral disorders like SARS, influenza and HIV/AIDS. His research is expected to produce novel approaches not only to diagnose and treat these illnesses but to prevent them. Dr. Chrétien was also Director of the Institut de recherches cliniques de Montréal and the OHRI before becoming involved with ICAV. Dr. Chrétien's has received many awards and honorary degrees and has published over 550 scientific articles.

Eleanor Fish - Canada

Dr. Fish's team studies interactions of cytokines, specifically interferons and chemokines, with their receptors at the conformational level, biological responses to these molecules and changes in expression of these molecules in diseased tissue. Since a chemokine receptor is a co-receptor for HIV, Dr. Fish is studying the role of this receptor in the entry of other viruses, poxviruses, into cells. A major focus in the lab is the study of virus-host interactions in the context of developing broad spectrum anti-virals. Through an examination of protein-protein interactions between ligands and receptors and between signaling effectors and viral intermediates, the researchers are able to translate this information into anti-viral drug development.

Anne Marie Hayes, Canada

Anne Marie Hayes graduated from the Michener Institute (Toronto Institute of Medical Technology) in 1986 as a Respiratory Therapist. With experience in both the hospital and home care setting, her clinical background includes critical care, trauma mangement, burn unit coverage, chronic care and pulmonary rehabilitation. In 2000, Anne Marie began working for a start-up Canadian pharmaceutical company as a Clinical Specialist, focusing on growing a global market and securing reimbursements in the US for this niche bronchoprovocation drug. Anne Marie has been a frequent speaker internationally in this field, assisting the clinical research field in particular in the use of this niche product. Having joined Hoffmann-La Roche in 2006 as a Medical Manager, Anne Marie now focuses on supporting the clinical management of influenza and helping Roche develop expanded knowledge to assist in pandemic planning.

Pierre J. Jeanniot - Canada

Director General Emeritus of the International Air Transport Association (IATA) and former President and CEO of Air Canada, Mr. Jeanniot is Chair of the Foundation for Anti-virals (FAV), a recently established charitable foundation that is affiliated with ICAV. Among his various interests and activities, Mr. Jeanniot is also Chancellor of the Université de Québec à Montréal and sits on the Board of Directors of numerous companies in Canada and around the world. Mr. Jeanniot continues to devote himself to many social and charitable causes in addition to FAV, and was for many years Honorary President of the Canadian Cancer Society Campaign and the Youth and Music Canada Foundation.

Arlene King – Canada

Dr. King was appointed as the Director General, Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada in December, 2007. She is an adjunct professor in the Faculty of Medicine, Department of Health Care and Epidemiology, University of British Columbia, Vancouver, Canada. She received her medical degree from McMaster University in Hamilton, Ontario in 1981, certification in Family Medicine from the University of Calgary, Alberta in 1984 and practiced Family Medicine in northern Alberta from 1985 to 1989. In 1990, she received a Masters Degree in Health Sciences from the University of British Columbia and in 1992, became a Fellow of the Royal College of Physicians and Surgeons of Canada in Community Medicine. She served as a medical officer of health in British Columbia, held various positions in communicable disease control at the British Columbia Centre for Disease Control in Vancouver and joined Health Canada/the Public Health Agency of Canada in 1999. Until her current appointment, and the creation of the new centre, she was the Director General for Pandemic Preparedness for the Agency.

In 2003, as the technical lead during the SARS response, she received Health Canada's Deputy Minister's Award of Merit for her contribution to Canada's National SARS Response. She has been a consultant to the World Health Organization on polio, SARS and influenza, to the World Bank and CIDA on Emerging Infectious Diseases and served on the Board of the Global Alliance on Immunization (GAVI) from 2004-2006. She is a member of the World Health Organization Africa Region Polio Eradication Certification Commission. She received the 2006 Chief Public Health Officer of Canada's Medal for establishing the Pandemic Preparedness Secretariat in the Public Health Agency, as Canada's focal point for health sector pandemic planning.

Janis Lazdins – Switzerland

Dr. Lazdins joined the Special Programme for Research and Training in Tropical Diseases (TDR) in 1998, working with the TDR/African Programme for Onchocerciasis Control (APOC)/Onchocerciasis Control Programme in West Africa (OCP). Dr. Lazdins' academic credentials includes 15 years of tenure at the Venezuelan Institute for Scientific Research, Harvard University, The National Institutes of Health, NCI, USA and Universita La Sapienza, Italy. Before joining TDR, Janis spent 12 years working for the pharmaceutical industry. Today his work focuses on product research and development with a spotlight on onchocerciasis, lymphatic filariasis, Chaga diseases and schistosomiasis. Dr. Lazdins is head of Drug Development and Evaluation for Helminths and Other Neglected Tropical Diseases and the Business Line Leader and Neglected Tropical Disease Research Coordinator.

Donald Low - Canada

Dr. Low's primary research interests are in the study of the epidemiology and the mechanisms of antimicrobial resistance in community and hospital pathogens. Other research interests include the epidemiology, pathogenesis, and treatment of streptococcal diseases. His group is recognized internationally for their Canadian population-based surveillance programs for the study of antimicrobial resistance and infectious diseases. Dr. Low is Head of the Department of Microbiology at the Toronto Medical Laboratories and Mount Sinai Hospital, a diagnostic laboratory serving 10 hospitals in the Greater Toronto Area. He is a Professor at the University of Toronto in the Department of Laboratory Medicine and Pathobiology and Department of Medicine. He is currently Head of the Division of Microbiology in the Department of Laboratory Medicine and Pathobiology.

Brian McCarthy – USA

Dr. McCarthy joined Merriman Curhan Ford & Co. in September 2006. He oversees equity research in the biotechnology sector. Prior to that, Dr. McCarthy served on the pharmacology faculty at the National Naval Medical Center's USUHS, served on the Neurology faculty at Cornell University Medical College, completed post-doctoral training at the Yale University School of Medicine, and consulted on Wall Street. In addition, he served as a research scientist at Trophix Pharmaceuticals prior to its acquisition by Allelix, and has authored numerous international peer-reviewed scientific publications. Dr. McCarthy earned a Ph.D. from SUNY Stony Brook and an M.S. from the University of Maryland. He is based in Merriman Curhan Ford & Co.'s New York office

Chris Miller – Canada

Dr. Chris Miller is a Research Associate at University of British Columbia in Dr. Av-Gay's Laboratory in the Division of Infectious Disease. He received his Associate Degree in respiratory therapy at the Northern Alberta Institute of Technology and undergraduate degree in Health Services Management at Ottawa University, Kansas City. Dr. Miller received his Doctorate in Experimental Medicine at the University of British Columbia. He is currently a member of the International Consortium for Antivirals and the American Respiratory Care Association. Before joining Dr. Av-Gay's laboratory team, he had established himself as a pioneer in nitric oxide technology and therapeutic research. Dr. Miller is well known because of his expertise in this field and has been a guest speaker throughout the world. He was recently presented the Jimmy Schultz Award for his contributions for innovative use of respiratory technologies for patient care. His involvement in the medical device industry is extensive and he is the author of numerous patents.

Claude P. Muller – Luxembourg

Dr. Muller is the Head, Department of Immunology at the Laboratoire National de Santé, Luxembourg. Research at the Institute focuses on the immune response against viruses and on their genotypic and phenotypic variability. Both physiological and pathophysiological immune reactions are under the influence and control of the neuroendocrine system. In particular, the immune response under stress is of major public health importance. Molecular mechanisms of the activity of stress response mediators, their receptors and their target genes are investigated. In particular, the gene structure, transcriptional and post-transcriptional regulation of glucocorticoid and other nuclear receptors, the structure of their DNA response elements and identification of target genes are of particular interest.

Lieve Naesens – Belgium

Dr. Naesens is an Associate Professor at the Rega Institute in Belgium. This institute is an inter-faculty biomedical research institute of the K.U. Leuven and consists of Departments of Medicine and Pharmacy. In 1987, the Rega Institute entered into a collaboration with Janssen Pharmacuetica, resulting in the discovery of a totally new class of HIV reverse transcriptase inhibitors, the so-called non-nucleoside RT Inhibitors. This research, in cooperation with Tibotec, resulted in a particular powerful anti-HIV compound, Rilpivirine (TMC-278). NNRTIs are at the moment considered one of the essential ingredients of so-called anti-HIV cocktails.

Oyekanmi Nashiru – Nigeria

After receiving his PhD in molecular genetics in Korea and completing post-doctoral training at the University of British Colombia and Albert Einstein College of Medicine in the United States, Dr. Nashiru returned to Nigeria and has since dedicated his career to improving opportunities for young African scientists. Dr. Nashiru is currently the coordinator of the National Biotechnology Center of Excellence at the University of Ibadan, and the Program Director for the West African Biotechnology Workshops Series (WABWS). Since 2002, WABWS, in collaboration with institutions in Canada, the USA, and the UK, has run annual capacity building workshops on biotechnology and bioinformatics in Nigeria. In 2003, Dr. Nashiru has been instrumental in the formation of the West African Biotechnology Network (WABNet). Dr. Nashiru provided the first characterization of the avian pathogenesis of African HPAI. Dr. Nashiru organized the First African Workshop/Symposium on Avian and Pandemic Influenza and Anti-Virals (May, 2007, Abuja, Nigeria), which was supported by the Nigerian government, the World Bank and ICAV. Dr. Nashiru is an adjunct lecturer at both the Universities of Ibadan and Abuja in Nigeria.

S.A. Omilabu – Nigeria

Dr. Omilabu is a Professor of Medical Virology in the department of Medical Microbiology and Parasitology at the College of Medicine of the University of Lagos, Nigeria. His specialty is the molecular epidemiology virus of public health

Albert Osterhaus – The Netherlands

Dr. Osterhaus is one of the world's leading virologists and his group was the first to identify human infection with the avian influenza strain H5N1. In 1997, his group discovered that a Hong Kong flu strain that had killed a three-year-old boy belonged to an avian influenza strain called H5N1. He was also the first scientist to show that H5N1 can be transferred into humans. In April 2003, at the height of the panic over SARS (Severe Acquired Respiratory Syndrome) in Hong Kong, he proved that the disease was caused by a newly discovered coronavirus that resides in civet cats, other carnivorous animals or bats. Currently he heads a 100-strong lab at Erasmus MC, Rotterdam, is the co-founder of two biotech companies, and is part of numerous global collaborations. He is particularly interested in viruses that cross species barriers, are highly pathogenic and which cause disease globally: viruses such as HIV, SARS CoV and influenza viruses.

Bonnie Patterson - Canada

Bonnie M. Patterson, BA, MLS, and member the ICAV Board of Directors, is an accomplished teacher, academic administrator, and dynamic leader, whose expertise in government relations and policy, and skills in institutional governance, aids ICAV's contributions to and relationships with, Canadian post secondary educational institutions and contributes to excellence in corporate governance. Since 1998, President and Vice-Chancellor of Trent University and Professor in Trent's Business Administration Department; was Dean, Faculty of Business, Professor, School of Administration and Information Management, and Special Assistant to the President of Ryerson University, Toronto; Chair of the Board of the Association of Universities and Colleges; Executive Committee of the Council of Ontario Universities and then President of the (COU); appointed to the Council of the Association of Commonwealth Universities, and serves on the Audit and Risk Committee; chaired the Board of the Peterborough Regional Health Centre, and continues as a Director; member Board of Directors, Greater Peterborough Region Innovation Cluster. President Patterson holds a BA and MLS from the University of Western Ontario.

JSM Peiris – Hong Kong

Dr. Peiris is in the Department of Microbiology University of Hong Kong. The research in his laboratory focuses on: Influenza (ecology, epidemiology, evolution and pathogenesis of animal and human influenza), the disease burden of human influenza and new diagnostic methods; Human herpesvirus 6 (HHV-6) and 7 (HHV-7); Virus-macrophage interactions; and pathogenesis and Clinical virology (diagnostic methods and clinical management).

Frank Plummer – Canada

Dr. Frank Plummer is the Chief Scientific Advisor, Public Health Agency of Canada, the Scientific Director General of the National Microbiology Laboratory in Winnipeg and Distinguished Professor at the University of Manitoba. He is recognized in Canada and abroad for his work in public health and science, having received numerous honours, including his appointment as Officer to the Order of Canada and induction into the Royal Society of Canada. He has been named Canada's Health Researcher of the year by the Canadian Institute of Health Research. He has also received a grant from the Grand Challenges in Global Health initiatives of the Bill & Melinda Gates Foundation for his HIV research and the St. Boniface Hospital Research Foundation International Award for work on HIV/AIDS in Africa.

Nabil Seidah - Canada

Dr. Seidah's research focuses on a family of eight mammalian proprotein convertases (PCs) and a metalloendopeptidase, NRDc. While serine proteinases are largely responsible for activating precursors of hormones, enzymes, growth and transcription factors, receptors, as well as envelope proteins of infectious viruses and bacteria, NRDc plays an important role in the cytosol and at the cell surface. Researchers on this team seek to define the mechanisms of action of these enzymes and their regulation, to isolate and produce specific inhibitors, and to determine the physiological roles of these enzymes and their clinical implications. In their work, they make use of novel techniques involving protein and peptide biochemistry, enzymology, molecular and cellular biology, affinity purification, proteomics as well as transgenic and knock-out mice.

Peter A. Singer- Canada

Professor Peter A. Singer is the Interim Director of the McLaughlin-Rotman Centre for Global Health, University Health Network and University of Toronto. At the University of Toronto, he is the Professor of Medicine. Prof. Singer, a leader in life sciences and global health, has made innovative contributions in taking science from the laboratory to the village. Dr. Singer has received Canada's highest health research awards including the Canadian Institutes of Health Research Distinguished Investigator Award and Michael Smith Award. He is a Fellow of the Canadian Academy of Health Sciences and the Royal Society of Canada.

Dr. Singer is a member of the Scientific Advisory Board of the Bill & Melinda Gates Foundation Grand Challenges for Global Health Initiative, a former member of the US National Academies Committee which reported on "Globalization, Biosecurity, and the Future of the Life Sciences", and he has advised the UN Secretary General's Office on biosecurity. He has published over 240 research articles, received over $50 million in research grants, trained over 70 graduate students and fellows, and written more than 30 op-eds in national newspapers. Between 1995 and 2006, Dr. Singer was Sun Life Financial Chair in Bioethics, Director of the World Health Organization Collaborating Centre for Bioethics at the University of Toronto, and Director of the University of Toronto Joint Centre for Bioethics. Singer studied internal medicine at the University of Toronto, medical ethics at the University of Chicago, public health at Yale University, and management at Harvard Business School.

The **McLaughlin-Rotman Centre for Global Health, Program on Life Sciences, Ethics and Policy** is based at the University Health Network and the University of Toronto. Created in 2001 and led by Professors Abdallah Daar and Dr. Singer, the program works at the nexus of life sciences, the developing world and entrepreneurship, using scholarly research to help move health technologies from "lab to the village." For more information please visit www.mrcglobal.org or visit 'Global Health Engage' on Facebook.

Eric R. Stephen - Canada

Mr. Stephen is the CBR Defence R&D Manager (Medical Interventions) in the Directorate Science and Technology Human Performance within Defence R&D Canada (DRDC). DRDC, an agency within the Canadian Department of National Defence, is responsible for the provision of leading-edge products and services in defence related science and technology to the Canadian Forces. His professional expertise covers the spectrum from bench research at Health Canada and the National Research Council of Canada through to biotechnology regulation development and scientific program development and management within the Department of Health. He has authored, co-authored and presented a number of scientific articles on a range of topics including microbiology, molecular biology and chemical and biological medical countermeasures. He has had broad experience in both national and international scientific fora in the governmental, industrial and academic sectors. He represents DRDC on a variety of national and international steering committees that address an array of chemical, biological, radiological and nuclear (CBRN) issues from funding first responder equipment needs to ensuring effective coordination of medical countermeasures R&D activities within and between governments.

Grant Tipler - Canada

Mr. Tipler is the head of the Life Sciences & Health Services team of the Knowledge Based Industries group at RBC Royal Bank. Grant has been instrumental in growing the Life Science practice since 1997 and making RBC the clear leader in banking this sector. Grant is a business coach to many life science businesses; new and mature companies alike seek his advice and counsel as they grow and transition. He works closely with other members of RBC, local venture capitalists, and other service providers to provide more than just money to this exciting and growing industry segment. Grant is active in the community where he is currently Chair & President of The Biotechnology Initiative. In 2005, he joined the Board of Directors for YORKbiotech, focusing on the convergence of IT and Medical Technologies in the York Region. He is also a member of the Advisory Board for the Master of Biotechnology program at the University of Toronto at Mississauga, and an active participant of the ViaTech groups in Burlington and Guelph, Ontario. A graduate of Dalhousie University in Halifax, Grant has a BSc and MBA in International Business.

Oyewale Tomori - Nigeria

Dr. Tomori is the University administrator and academician, and Vice Chancellor, Redeemer's University, Ogun State, Nigeria. He served from 1994-2004 as the Regional Virologist and Laboratory Coordinator, World Health Organization, (Africa Region), and has wide ranging experience in virology, disease prevention and control, national capacity building and development in the African region.

Anna Vyakarnam – United Kingdom

Dr. Vyakarnan is a Senior Lecturer in the Department of Infectious Diseases at King's College London School of Medicine at Guy's, King's and St Thomas' Hospitals. One objective of her group is to identify and characterize host cell factors that regulate HIV infection. Her strategy is based on the knowledge that human CD4 T-cells of the same genetic origin can differ substantially in their susceptibility to HIV infection despite expression of the critical HIV receptor / coreceptors.

John Wilkinson - Canada, Minister of Research and Innovation, Government of Ontario, Canada

Mr. Wilkinson was first elected to the Ontario legislature in 2003 as the MPP for Perth-Middlesex. He was re-elected in 2007 as the MPP for Perth-Wellington. Wilkinson previously served as the Parliamentary Assistant to Premier Dalton McGuinty in his capacity as Ontario's first Minister of Research and Innovation. He has also served as the Parliamentary Assistant to the Minister of the Environment and was appointed by the Minister of Finance to serve as the vice chair of the Municipal Property Assessment Corporation. Wilkinson is the first Certified Financial Planner elected to the Ontario legislature. Known for his lengthy record of service, Wilkinson has been very active in both his church and community. He was both the youngest president and senior member of the Kiwanis Club of Stratford and most recently chaired a $1.5 million fundraising campaign in support of the Discovery Centre, situated beside the Stratford Festival in the historic Stratford Normal School.

Jonathan P. Wong - Canada

J.P. Wong has been a research scientist with Defense R&D Canada – Suffield (DRDC Suffield) for more than 20 years. He has published more than 100 journal and conference papers in the areas of infectious diseases, drug and vaccine development, drug delivery systems and molecular biology. His major areas of research include medical countermeasures against biological agents, drug and vaccine development, development of novel prophylaxis and treatment against influenza virus infection, respiratory infections and aerosol delivery of drugs and vaccines. J.P. Wong received his undergraduate and graduate degrees in Biochemistry from University of Saskatchewan, Canada. He completed his graduate research at the Department of Veterinary Physiological Sciences, Western College of Veterinary Medicine at the University of Saskatchewan.

Paul Zhou – China

Dr. Zhou is Principal Investigator, Antiviral Immunity and Genetic Therapy Unit at the Institut Pasteur of Shanghai, Chinese Academy of Sciences (IPS-CAS). His laboratory has three major research areas: to develop a membrane-bound antibody-based strategy for HIV**;** to design particle-based immunogens for vaccines against HIV; and to develop influenza HA/NA/M2 pseudotyped lentiviral vectors for various applications.